{"id":"NCT00984867","sponsor":"AstraZeneca","briefTitle":"Dapagliflozin DPPIV Inhibitor add-on Study","officialTitle":"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-03","completion":"2011-09","firstPosted":"2009-09-25","resultsPosted":"2013-10-14","lastUpdate":"2014-06-13"},"enrollment":833,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change in HbA1c Levels","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.04,"sd":0.0509},{"arm":"Dapagliflozin","deltaMin":-0.45,"sd":0.0509}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":88,"countries":["United States","Argentina","Germany","Mexico","Poland","United Kingdom"]},"refs":{"pmids":["24144654","38770818"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=292&filename=D1690C00010_Study_Synopsis_1Mar2012.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=292&filename=D1690C00010_Revised_CSP1_and_Amdt_1_Priv_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":226},"commonTop":["Nasopharyngitis"]}}